方法对比
并排查看您选择的方法；存在差异的行会高亮显示。
| 连线测验× | 阿尔茨海默病评估量表-认知功能部分× | |
|---|---|---|
| 领域 | 神经心理学 | 神经心理学 |
| 方法族 | Process / pipeline | Process / pipeline |
| 起源年份≠ | 1958 | 1984 |
| 提出者≠ | Ralph Reitan | William Rosen |
| 类型≠ | Clinician-administered neuropsychological test of attention and executive function | Clinician-administered cognitive scale for Alzheimer's disease |
| 开创性文献≠ | Reitan, R. M. (1958). Validity of the Trail Making Test as an indicator of organic brain damage. Perceptual and Motor Skills, 8(3), 271-276. DOI ↗ | Rosen, W. G., Mohs, R. C., & Davis, K. L. (1984). A new rating scale for Alzheimer's disease. American Journal of Psychiatry, 141(11), 1356-1364. DOI ↗ |
| 别名≠ | TMT, Trails A, Trails B, Trail Making A | ADAS-Cog, ADAS-Cog14, ADAS-Cog13 |
| 相关 | 5 | 5 |
| 摘要≠ | The Trail Making Test (TMT) is a simple, brief neuropsychological test developed by Reitan in 1958 that measures visuomotor processing speed, attention, and executive function. The TMT comprises two forms: Part A, which assesses basic processing speed and visual scanning, and Part B, which assesses executive function, task-switching, and cognitive flexibility. Despite its simplicity, the TMT is highly sensitive to cognitive impairment across a wide range of neurological and psychiatric conditions and remains one of the most widely used screening tests in neuropsychology. | The Alzheimer's Disease Assessment Scale-Cognitive (ADAS-Cog) is a clinician-administered cognitive assessment instrument designed specifically to measure cognitive decline in Alzheimer's disease. Developed by Rosen, Mohs, and Davis in 1984 and published in the American Journal of Psychiatry, the ADAS-Cog has become the gold standard outcome measure in pharmaceutical trials of antidementia drugs. It is sensitive to disease progression and capable of detecting cognitive change over periods as brief as 6–12 months. |
| ScholarGate数据集 ↗ |
|
|